Jessica Mwinyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jessica Mwinyi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Isa Cavaco
Institute of Biotechnology and Bioengineering, Center of Molecular and Structural Biomedicine, University of Algarve
3 shared publications Magnus Ingelman-Sundberg
3 shared publicationsSouren Mkrtchian
3 shared publications- Jana Nekvindová
University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
2 shared publications Rasmus Steen Pedersen
Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, S-17177 Stockholm, Sweden
2 shared publicationsYvonne Hofmann
Karolinska Inst, Dept Physiol & Pharmacol, Pharmacogenet Sect, S-17177 Stockholm, Sweden
2 shared publications
Latest Publications
- 1 July 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 338 (1) , 302-309
The Ligands of Estrogen Receptor α Regulate Cytochrome P4502C9 (CYP2C9) Expression
Cytochrome P4502C9 (CYP2C9) is an important drug-metabolizing enzyme responsible for the metabolism of approximately 16% of all clinically relevant drugs. It was shown previously that the activity of CYP2C9 in vivo is inhibited by oral contraceptives. The mechanisms of this effect have not been elucidated. We hypothesize that this may occur because of the sex steroid-dependent activation of estrogen receptor α (ERα) with further transactivation of the CYP2C9 gene. Here, we show that the CYP2C9 promoter indeed contains a functionally relevant estrogen responsive element (ERE) half-site at position −149/−145. Its ERα binding activity was tested by the luciferase gene reporter assay. Promoter constructs bearing this site were cotransfected with ERα into Huh7 hepatoma cells and treated with various ERα ligands including 4-hydroxytamoxifen (4-OHT), raloxifene (R), 17β-estradiol (EE), and 17α-ethinylestradiol (ETE). The luciferase activity driven by the wild-type CYP2C9 promoter construct was up-regulated by 4-OHT and R and significantly or marginally suppressed by ETE and EE, respectively. An identical effect was observed in primary hepatocytes treated with these compounds. Mutations introduced into the ERE half-site abolished the observed effects in the Huh7 cells. Electrophoretic mobility-shift assay revealed sequence-specific binding of a nuclear protein to the oligonucleotide containing the ERE half-site, which was identified as ERα by antibody supershift analysis. In addition, the association of ERα with CYP2C9 promoter was strongly supported by chromatin immunoprecipitation data. Taken together, these results indicate that ERα and its ligands play an important role in the regulation of CYP2C9 expression.
- 1 July 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 338 (1) , 302-309
The Ligands of Estrogen Receptor α Regulate Cytochrome P4502C9 (CYP2C9) Expression
Cytochrome P4502C9 (CYP2C9) is an important drug-metabolizing enzyme responsible for the metabolism of approximately 16% of all clinically relevant drugs. It was shown previously that the activity of CYP2C9 in vivo is inhibited by oral contraceptives. The mechanisms of this effect have not been elucidated. We hypothesize that this may occur because of the sex steroid-dependent activation of estrogen receptor α (ERα) with further transactivation of the CYP2C9 gene. Here, we show that the CYP2C9 promoter indeed contains a functionally relevant estrogen responsive element (ERE) half-site at position −149/−145. Its ERα binding activity was tested by the luciferase gene reporter assay. Promoter constructs bearing this site were cotransfected with ERα into Huh7 hepatoma cells and treated with various ERα ligands including 4-hydroxytamoxifen (4-OHT), raloxifene (R), 17β-estradiol (EE), and 17α-ethinylestradiol (ETE). The luciferase activity driven by the wild-type CYP2C9 promoter construct was up-regulated by 4-OHT and R and significantly or marginally suppressed by ETE and EE, respectively. An identical effect was observed in primary hepatocytes treated with these compounds. Mutations introduced into the ERE half-site abolished the observed effects in the Huh7 cells. Electrophoretic mobility-shift assay revealed sequence-specific binding of a nuclear protein to the oligonucleotide containing the ERE half-site, which was identified as ERα by antibody supershift analysis. In addition, the association of ERα with CYP2C9 promoter was strongly supported by chromatin immunoprecipitation data. Taken together, these results indicate that ERα and its ligands play an important role in the regulation of CYP2C9 expression.
- 8 May 2010
- Published by Elsevier in Life Sciences
- Vol. 86 (19-20) , 699-706
The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression
- 8 May 2010
- Published by Elsevier in Life Sciences
- Vol. 86 (19-20) , 699-706
The transcription factor GATA-4 regulates cytochrome P4502C19 gene expression
- Open Access
- 1 March 2010
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (3) , 415-421
New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4
CYP2C9 is an important drug-metabolizing enzyme that metabolizes, e.g., warfarin, antidiabetics, and antiphlogistics. However, the endogenous regulation of this enzyme is largely unknown. In this study, we examined the role of GATA transcription factors in the gene expression of CYP2C9. We investigated four putative GATA binding sites within the first 200 base pairs of CYP2C9 promoter at the positions I: −173/−170, II: −167/−164, III: −118/−115, and IV: −106/−103. Luciferase activity driven by a wild-type CYP2C9 promoter construct was strongly up-regulated in Huh-7 cells upon cotransfection with expression plasmids for GATA-2 and GATA-4, whereas mutations introduced into GATA binding site III or I and II reduced this induction to a significant extent. Electrophoretic mobility shift assays revealed specific binding of GATA-4 and GATA-6 to the oligonucleotides containing GATA binding sites I and II. Furthermore, the association of GATA-4 with CYP2C9 promoter was confirmed by chromatin immunoprecipitation assays in HepG2 cells. Taken together, these data strongly suggest an involvement of liver-specific transcription factor GATA-4 in the transcriptional regulation of CYP2C9.
- 1 March 2010
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (3) , 415-421
Open AccessNew Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4
CYP2C9 is an important drug-metabolizing enzyme that metabolizes, e.g., warfarin, antidiabetics, and antiphlogistics. However, the endogenous regulation of this enzyme is largely unknown. In this study, we examined the role of GATA transcription factors in the gene expression of CYP2C9. We investigated four putative GATA binding sites within the first 200 base pairs of CYP2C9 promoter at the positions I: −173/−170, II: −167/−164, III: −118/−115, and IV: −106/−103. Luciferase activity driven by a wild-type CYP2C9 promoter construct was strongly up-regulated in Huh-7 cells upon cotransfection with expression plasmids for GATA-2 and GATA-4, whereas mutations introduced into GATA binding site III or I and II reduced this induction to a significant extent. Electrophoretic mobility shift assays revealed specific binding of GATA-4 and GATA-6 to the oligonucleotides containing GATA binding sites I and II. Furthermore, the association of GATA-4 with CYP2C9 promoter was confirmed by chromatin immunoprecipitation assays in HepG2 cells. Taken together, these data strongly suggest an involvement of liver-specific transcription factor GATA-4 in the transcriptional regulation of CYP2C9.